Apoptosis

, Volume 2, Issue 2, pp 227–238 | Cite as

Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: Association of the therapeutic effect with differentiation and apoptosis in the cancer cells

  • M. Sato
  • K. Harada
  • H. Yoshida
  • Y. Yura
  • M. Azuma
  • H. Iga
  • T. Bando
  • H. Kawamata
  • Y. Takegawa
Article

Abstract

Twenty patients with oral squamous cell carcinoma having mainly stage II or III lesions without distant metastasis, were treated with tegafur and streptococcal agent, OK-432, in combination with radiotherapy. As a consequence, 16 cases among the treated 20 cases showed complete remission by this therapy alone. Especially, we have found that the squamous cell carcinoma arising in non-keratinizing oral epithelium rather than in keratinizing oral epithelium has better response to this therapy. Among the 16 cases with complete remission (CR) by the current therapy, 10 cases were histopathologically diagnosed as well-differentiated squamous cell carcinoma and six cases as moderately differentiated squamous cell carcinoma. When we examined immunohistochemically the expres-sion of various antigens such as proliferating cell nuclear antigen (PCNA), p53 and LeY or the presence of DNA fragmentation by nick-end labelling in the biopsy materials taken at the first visit to our clinic from 20 patients treated with the current therapy, the CR group showed a significantly increased LeY expres-sion level ( p< 0.05) and DNA fragmentation rate ( p< 0.05) as compared with the partial response (PR, n= 3) + no change (NC, n= 1) group. On the other hand, the CR group with respect to PCNA expression level was significantly decreased as compared with the PR + NC group ( p< 0.05). From these findings, it can be considered that the therapy for oral squamous cell carcinoma by UFT and OK-432 in combination with radiotherapy is very effective, which may be associated with differentiation or apoptosis in oral squamous carcinoma cells. In addition, we present the clinical findings and results of immunohistochemical staining for the biopsy materials obtained from four CR cases treated with the current therapeutic method.

Apoptosis differentiation OK-432 oral squamous cell carcinoma radiotherapy tegafur 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johnson NW. Epidemiology of oral cancer in risk markers of oral disease. In: Johnson NW, ed. Oral Cancer, Vol. 2. Cambridge, UK: Cambridge University Press, 1991: 3–26.Google Scholar
  2. 2.
    Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States 1947–1984. JNCI 1987; 4: 701–770.Google Scholar
  3. 3.
    Voravud N. Cancer in the far east. In: Sikara K, Halnan KE, eds. Treatment of Cancer, Second Edition. London, UK: Chapman and Hall Medical, 1990: 887–894.Google Scholar
  4. 4.
    Wolf G, Lippman SM, Laramore G, et al. Head and neck cancer. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DC, Weischelbaum R, eds. Cancer Medicine, Third Edition. Philadelphia, PA (USA): Lea and Febiger, 1990: 887–894.Google Scholar
  5. 5.
    Binnie WH, Cawson RA, Hill GB, Soaper AE. Oral cancer in England and Wales. Series SMPS No. 23. London, UK: HMSO, 1972: 25–48.Google Scholar
  6. 6.
    Silberberg E, Lubera J. Cancer Statistics 1987, CA. 1987; 37: 2–9.Google Scholar
  7. 7.
    Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother 1988; 22: 333–338.Google Scholar
  8. 8.
    Creaven PJ, Rustum YM, Petrelli NJ, Gorbunova VA. Clinical studies of the modulation of Ftorafur. In: Rustum YM, ed. Novel Approaches to Selective Treatments of Human Solid tumors: Laboratory and Clinical Correlation. New York, NY (USA): Raven Press, 1993: 253–262.Google Scholar
  9. 9.
    Yamanoto J, Toide K, Haruno A, Yoshimura Y, Unemi N. General pharmacological properties of UFT, a new type of anticancer agent consisting of 1(2-tetrahydrofurayl)-5-fluorouracil (FT) and uracil. Drug Res 1981; 31: 1268–1278.Google Scholar
  10. 10.
    Hiller SA, Zhuk RA, Lidaks M, Ziderman A. Analogs of pyrimidine nucleoside. 1. N1-(α-tetrahydrofuryl) derivatives of natural pyrimidine bases and their metabolites. Dokl Akad Natuk SSSR 1967; 176: 332–335.Google Scholar
  11. 11.
    Smolyanskaya AZ, Tugarinor OA. The biological activity of antitumour antimetabolite ‘Ftorafur’. Neoplasma 1972; 19: 341–345.Google Scholar
  12. 12.
    Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2′-tetrahydrofuranyl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209–214.Google Scholar
  13. 13.
    Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming ability of hemolytic streptococci. Jpn J Microbiol 1967; 11: 323–336.Google Scholar
  14. 14.
    Ono T, Kurata S, Wakabayashi K, Sugawara, Y, Saito M, Ogawa H. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gann 1973; 64: 59–69.Google Scholar
  15. 15.
    Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagashi Y. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep 1972; 56: 9–17.Google Scholar
  16. 16.
    Okamoto H, Shoin S, Koshimura, S. Streptolysin S-forming and anticancer activities of group A streptococci. In: Jeljaszewicz J, Wadstrom T, eds. Bacterial Toxin and Cell Membranes. New York, NY (USA): Academic Press, 1978: 259–289.Google Scholar
  17. 17.
    Ishii Y, Yamaoka H, Toh K, Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann 1976; 67: 115–119.Google Scholar
  18. 18.
    Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. JNCI 1980; 65: 1265–1269.Google Scholar
  19. 19.
    Oshimi K, Wakasugi H, Seki H, Kano S. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Cancer Immunol Immunother 1980; 9: 187–192.Google Scholar
  20. 20.
    Matsubara S, Suzuki F, Ishida N. Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Cancer Immunol Immunother 1979; 6: 41–45.Google Scholar
  21. 21.
    Sato M, Yoshida H, Yanagawa T, et al. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 1984; 13: 7–15.Google Scholar
  22. 22.
    Hoshino T, Iho S, Kura F, Uchida A. In vivo and in vitro biological effects of OK-432, a streptococcal preparation, on the augmentation of autologous tumor cell killing activity and cytokine production of lymphocytes and monocytes in malignant diseases. In: Micksche M, Klein E, eds. OK-432. A Biological Response Modifier. Tokyo, Japan: Professional Postgraduate Services, International, 1986: 61–68.Google Scholar
  23. 23.
    Nagamuta M, Yamamoto S, Usami Y, et al. Induction of TNF in peritoneal fluid of mice treated with OK-432. In: Ishida N, ed. Mechanisms of Antitumor Effects of OK-432. Tokyo, Japan: Excerta Medica, 1986; 126–136.Google Scholar
  24. 24.
    Djeu JY, Henbaugh JA, Holden HT, Herberman RB. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 1979; 122: 175–181.Google Scholar
  25. 25.
    Herberman RB, Ortaldo JR, Mantovani A, et al. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982; 67: 160–167.Google Scholar
  26. 26.
    Peri G, Polentaruti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokine and endotoxin. Int J Cancer 1981; 28: 143–152.Google Scholar
  27. 27.
    Yanagawa E, Toge T, Niimoto M, Hattori T. In vitro augmentation of natural and autotumor killing activity of tumor-associated macrophages by OK-432, interleukin-2, and interferon. In: Hoshino T, ed. Immunopharmacological Aspects of OK-432 in Humans. Tokyo, Japan: Excerpta Media, 1986: 17–26.Google Scholar
  28. 28.
    Gidlund M, Orn S, Wizzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978; 273: 759–761.Google Scholar
  29. 29.
    Schultz RM, Papamatheakis ID, Chirigos MA. Functional and morphologic characteristics of interferon-treated macrophages. Cell Immunol 1978; 35: 84–91.Google Scholar
  30. 30.
    Okamoto M, Kaji R, Kasetani H, et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J Immunother 1993; 13: 232–242.Google Scholar
  31. 31.
    Takada H, Kawabata Y, Arakaki R, et al. Molecular and structural requirements of a lipoteichoic acid from Enterococcus hirae ATCC 9790 for cytokine-inducing, antitumor, and antigenic activities. Infect Immun 1995; 63: 57–65.Google Scholar
  32. 32.
    Schwartz EL, Holfman M, O'Connor C, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1991; 182: 1232–1239.Google Scholar
  33. 33.
    Cascinu S, Del Ferro E, Fedeli A, et al. Cytokinetic effects of interferon in colorectal cancer tumors: Implications in the design of the interferon/5-fluorouracil combinations. Cancer Res 1993; 53: 5429–5432.Google Scholar
  34. 34.
    International Union Against Cancer. TNM Classification of Malignant Tumors, 4th Edition. Oral Cavity. Geneva, Switzerland: International Union Against Cancer, 1987: 16–18.Google Scholar
  35. 35.
    Wahi PN, Cohen B, Luthra UK. Histological typing of oral and oropharyngeal tumors. In: World Health Organization. International Histological Classification of Tumors, No. 4. Geneva, Switzerland: WHO, 1971.Google Scholar
  36. 36.
    Shi SR, Key MC, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissue: an enhancement method for immunohistochemical staining based on microwave open-heating of tissue sections. J Histochem Cytochem 1991; 39: 741–748.Google Scholar
  37. 37.
    Hsu S-M, Ralne L, Franger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–580.Google Scholar
  38. 38.
    Abe K, McKibbin J, Hakomori S. The monoclonal antibody directed to difucosylated type 2 chain (Fucα1–2Galβ1–4[Fucα1–3]GlcNAc: Y determinant. J Biol Chem 1983; 258: 11793–11797.Google Scholar
  39. 39.
    Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501.Google Scholar
  40. 40.
    Crowe DL, Hu L, Gudas LJ, Rheinwald JG. Variable expression of retinoic acid receptor (RAR beta) mRNA in human oral and epidermal keratinocytes; relation to keratin 19 expression and keratinization potential. Differentiation 1991; 48: 199–208.Google Scholar
  41. 41.
    Uchida A, Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. Cancer 1980; 45: 476–483.Google Scholar
  42. 42.
    Watanabe S, Sendo F, Kimura S, Arai S. Activation of cytotoxic polymorphonuclear leukocytes by in vitro administration of a streptococcal preparation, OK-432. JNCI 1984; 72: 1365–1370.Google Scholar
  43. 43.
    Saito M, Nanjo M, Aonuma E, et al. Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer 1984; 33: 271–276.Google Scholar
  44. 44.
    Talmage IE, Herberman RB. Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 1986; 70: 171–182.Google Scholar
  45. 45.
    Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. JNCI 1983; 71: 673–680.Google Scholar
  46. 46.
    Hojo H, Hashimoto Y. Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432). Gann 1981; 72: 692–699.Google Scholar
  47. 47.
    Saito M, Nanjo M, Kataoka M, et al. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res 1988; 48: 4163–4167.Google Scholar
  48. 48.
    Moriya Y, Sato H, Ito K, Saito M, Yoshida T, Ishida T. Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice. Cancer Immunol Immother 1993; 36: 245–250.Google Scholar
  49. 49.
    Hayashi Y, Nishida T, Yoshida H, et al. Peripheral K-lymphocyte population in head and neck cancer. Cancer 1984; 53: 2507–2514.Google Scholar
  50. 50.
    Hayashi Y, Yoshida H, Yamashita T, et al. Phenotypic and functional characterization of peripheral natural killer cell population in squamous cell head and neck cancer. Cancer J 1987; 1: 353–357.Google Scholar
  51. 51.
    Sato M. Treatment of oral cancer. Asian J Oral Maxillofac Surg 1993; 5: 87–99.Google Scholar
  52. 52.
    Pak AS, Wright MA, Matthews JP, et al. Mechanisms of immune suppression in patients with head and neck cancer: Presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Res 1995; 1: 95–103.Google Scholar
  53. 53.
    Pak AS, Ip G, Wright MA, Young MRI. Treating tumor-bearing mice with low-dose γ-interferon plus tumor necrosis factor α to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 1995; 55: 885–890.Google Scholar
  54. 54.
    Letessier EM, Sacchi M, Joshson JT, Herberman RB, Whiteside TL. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 1990; 130: 446–458.Google Scholar
  55. 55.
    Dziarski R, Gupta D. Heparin, sulfatd heparinoids, and lipoteichoic acids bind to 70-kDa peptidoglycan/lipopolysaccharide receptor protein on lymphocytes. J Biol Chem 1994; 269: 2100–2110.Google Scholar
  56. 56.
    Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 1990; 81: 1039–1044.Google Scholar
  57. 57.
    Inaba M, Mitsuhashi J, Ozawa S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 1990; 81: 1039–1044.Google Scholar
  58. 58.
    Inaba M, Mitsuhash J. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. Oncol Res 1994; 6: 303–309.Google Scholar
  59. 59.
    Waxman S, Scher BM, Hellinger N, Scher W. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 1990; 50: 3878–3887.Google Scholar
  60. 60.
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 959–967.Google Scholar
  61. 61.
    Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353–2362.Google Scholar
  62. 62.
    Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473–3486.Google Scholar
  63. 63.
    Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775.Google Scholar
  64. 64.
    Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027–2031.Google Scholar
  65. 65.
    Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1991; 9: 1806–1810.Google Scholar
  66. 66.
    Schwartz EL, Hoffman M, O'Connor C, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1991; 182: 1232–1239.Google Scholar
  67. 67.
    Vogelstein B. Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523–526.Google Scholar
  68. 68.
    Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–6311.Google Scholar
  69. 69.
    Nagasawa H, Robertson J, Arundel CS, Little JB. The effect of X-irradiation on the progression of mouse 10T1/2 cells released from density-inhibited cultures. Radiat Res 1984; 97: 537–545.Google Scholar
  70. 70.
    Kuerbitz L, Plunkett BS, Walsh WW, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491–7495.Google Scholar
  71. 71.
    Ward JF. DNA damage as the cause of ionizing radiation-induced gene activation. Radiat Res 1994; 138(Suppl 1): S85–S88.Google Scholar
  72. 72.
    Jung M, Notario V, Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and-resistant human squamous carcinoma cells. Cancer Res 1992; 52: 6390–6393.Google Scholar
  73. 73.
    Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993; 53: 3667–3669.Google Scholar
  74. 74.
    Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989; 264: 13856–13864.Google Scholar
  75. 75.
    Mercer WE, Shields MT, Lin D, Appella E, Ullrich SL. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991; 88: 1958–1962.Google Scholar
  76. 76.
    Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285–294.Google Scholar
  77. 77.
    Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immnochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893–899.Google Scholar
  78. 78.
    Chen PI, Chen Y, Bookstein R, Lane DP. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–1580.Google Scholar
  79. 79.
    Marks J, Davidoff A, Kerns B, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979–2984.Google Scholar
  80. 80.
    Visakori T, Kallinoiemi OP, Heikkinen AT, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. JNCI 1992; 84: 883–887.Google Scholar
  81. 81.
    Hiraishi K, Suzuki K, Hakomori SI, Adachi M. LeY antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993; 3: 381–390.Google Scholar

Copyright information

© Chapman and Hall 1997

Authors and Affiliations

  • M. Sato
    • 1
  • K. Harada
    • 1
  • H. Yoshida
    • 1
  • Y. Yura
    • 1
  • M. Azuma
    • 1
  • H. Iga
    • 1
  • T. Bando
    • 1
  • H. Kawamata
    • 1
  • Y. Takegawa
    • 2
  1. 1.Second Department of Oral and Maxillofacial SurgeryTokushima University School of DentistryTokushimaJapan
  2. 2.Department of Radiological TechnologyTokushima University School of Medical SciencesTokushimaJapan

Personalised recommendations